Devonian Health Group Inc. (TSXV:GSD)
10.00
0.00 (0.00%)
At close: Feb 9, 2026
Devonian Health Group Revenue
In the fiscal year ending July 31, 2025, Devonian Health Group had annual revenue of 23.59M CAD with 22.19% growth. Devonian Health Group had revenue of 1.28M in the quarter ending July 31, 2025, a decrease of -87.40%.
Revenue
23.59M
Revenue Growth
+22.19%
P/S Ratio
1.49
Revenue / Employee
1.85M
Employees
11
Market Cap
27.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jul 31, 2025 | 23.59M | 4.28M | 22.19% |
| Jul 31, 2024 | 19.31M | 16.96M | 723.15% |
| Jul 31, 2023 | 2.35M | 40.20K | 1.74% |
| Jul 31, 2022 | 2.31M | 830.50K | 56.32% |
| Jul 31, 2021 | 1.47M | -668.47K | -31.19% |
| Jul 31, 2020 | 2.14M | -1.86M | -46.49% |
| Jul 31, 2019 | 4.00M | 837.05K | 26.42% |
| Jul 31, 2018 | 3.17M | - | - |
| Jul 31, 2017 | - | - | - |
| Jul 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Microbix Biosystems | 18.59M |
| Telescope Innovations | 6.28M |
| Rapid Dose Therapeutics | 2.78M |
| Britannia Life Sciences | 260.58K |
| MedMira | 232.99K |
Devonian Health Group News
- 2 months ago - Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update - Benzinga
- 8 months ago - Passion, Plants, and Phase III: Devonian Health Group Is on a Mission to Disrupt Inflammation Therapy - IBTimes
- 10 months ago - Devonian Health Group Announces Reinstatement of Quotation on the TSXV - Financial Post
- 1 year ago - Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis - Financial Post
- 1 year ago - Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Financial Post
- 1 year ago - Devonian Health Group Inc. Reports Superior Anti-Inflammatory Potency of Thykamine™ in Comparative In Vitro Study - Financial Post